Search clinical trials for: Glycopyrronium Bromide

Total 928 results

Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen

COPD

Germany, Belgium, Poland, Romania, Italy, Spain, Estonia, Russian Federation, Austria, France, Slovakia, Czechia, Latvia, Lithuania, Greece, Hungary, United Kingdom, Portugal, Ireland, Norway, Slovenia, Denmark, Sweden
Novartis Pharmaceuticals

Recruiting

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

Asthma

Spain, Hungary, United Kingdom, South Africa, Colombia, Bulgaria, Poland, Guatemala
Novartis

Completed

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) (GLOW2)

Chronic Obstructive Pulmonary Disease

United States, Argentina, Germany, Russian Federation, France, Israel, Korea, Republic of, Italy, Poland, Chile, Mexico, Peru, Canada, Hungary, Netherlands, New Zealand
University of Saskatchewan

Completed

Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve

Asthma

Canada
Daewoong Pharmaceutical Co. LTD.

Completed

Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

COPD

Korea, Republic of
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

China
AstraZeneca

Completed

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35) (LAS-MD-35)

Chronic Obstructive Pulmonary Disease

United States, Canada
Prosonix Limited

Completed

Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United Kingdom
Dr. August Wolff GmbH & Co. KG Arzneimittel

Completed

Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis

Primary Axillary Hyperhidrosis

Germany
AstraZeneca

Completed

Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)

Chronic Obstructive Pulmonary Disease

United States, Canada
AstraZeneca

Completed

Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients. (ASCENT COPD)

Chronic Obstructive Pulmonary Disease | COPD | Moderate to Very Severe COPD

United States, Canada
AstraZeneca

Completed

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38) (LAS-MD-38)

Chronic Obstructive Pulmonary Disease

United States, Canada
AstraZeneca

Completed

A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Andorra, Austria, Belgium, Bulgaria, Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Romania, Russian Federation, Spain, United Kingdom
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide 400 µg BID (Twice a Day)Compared to Placebo in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, United Kingdom
Botanix Pharmaceuticals

Completed

A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis

Primary Axillary Hyperhidrosis

United States
AstraZeneca
Menarini Group

Completed

BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH (M-34273-46)

Pulmonary Disease, Chronic Obstructive

Italy, Spain, United Kingdom, Germany, Hungary
AstraZeneca

Completed

A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Canada
AstraZeneca

Completed

Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Argentina, Australia, Canada, Mexico, New Zealand, South Africa
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)

Chronic Obstructive Pulmonary Disease

United States, Canada
Novartis Pharmaceuticals

Completed

Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients (FAVOR)

Chronic Obstructive Pulmonary Disease | COPD

Germany
AstraZeneca

Completed

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Czech Republic, France, Hungary, Italy, Peru, Poland, Russian Federation, South Africa, Spain, Ukraine
Novartis Pharmaceuticals

Completed

Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

Asthma

Germany, United States, Belgium, Latvia, Lithuania, Japan
Botanix Pharmaceuticals

Completed

Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302) (Cardigan II)

Axillary Hyperhidrosis

United States
AstraZeneca

Completed

A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants

Healthy Volunteers

China
Rain Oncology Inc

Terminated

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN)

NSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB Fusion

United States, Canada, Hong Kong
Cothera Bioscience, Inc

Recruiting

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphatic Diseases | Burkitt Lymphoma | High-grade B-cell Lymphoma | C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma | C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma | Lymphoma, High-Grade | C-Myc Gene Rearrangement

Korea, Republic of, China
University of Milan
Fondazione Salvatore Maugeri

Completed

Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients

Chronic Obstructive Pulmonary Disease

Italy
NPO Petrovax

Completed

Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19

Infections, Coronavirus

Belarus, Russian Federation
GlaxoSmithKline

Completed

A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)

Pulmonary Disease, Chronic Obstructive

China, Korea, Republic of
AstraZeneca

Completed

A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany
Novartis

Completed

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States, Spain, Turkey, France, Netherlands, Germany
Novartis

Completed

A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo (GLOW 1)

Chronic Obstructive Pulmonary Disease

Russian Federation, Singapore, United States, Canada, Korea, Republic of, Japan, Spain, Turkey, Romania, Australia, Netherlands
Mersey Care NHS Trust
University of Central Lancashire; University of Manchester; Lancashire Care NHS... and other collaborators

Completed

Clozapine-induced Hypersalivation - Feasibility Trial (GOTHIC1)

Sialorrhea

United Kingdom
Novartis Pharmaceuticals

Completed

Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BRIGHT)

COPD

Germany, Spain
Botanix Pharmaceuticals

Completed

A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis

Primary Axillary Hyperhidrosis

United States
NPO Petrovax

Active, not recruiting

Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19

Infections, Coronavirus

Russian Federation, Slovakia
Children's Hospital of Philadelphia
Auto Dealers Caring for Kids Foundation

Completed

Fluid Filled Lung Oxygenation Assistance Trial (FFLOAT)

Bronchopulmonary Dysplasia

United States
Sunovion Respiratory Development Inc.

Completed

Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). (GOLDEN7)

COPD

United Kingdom
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of QVA149 in COPD Patients

Chronic Obstructive Pulmonary Disease

United States
Samsung Medical Center

Recruiting

Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery

Chronic Obstructive Pulmonary Disease | Non Small Cell Lung Cancer

Korea, Republic of
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366

Chronic Obstructive Pulmonary Disease | Asthma

United Kingdom
GlaxoSmithKline

Completed

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (DB2113361)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Ukraine, Estonia, Belgium, France, Sweden, Netherlands, Philippines, Denmark, Hungary, Norway, Slovakia
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (GLOW6)

Chronic Obstructive Pulmonary Disease (COPD)

Greece, Belgium, Bulgaria, Turkey, Hungary, Slovakia, Spain, United Kingdom, Russian Federation, Ireland
Rajesh Deshar

Completed

Effect of Glycopyrrolate on Vasopressors Requirement for Non-elective Caesarean Section Under Spinal Anaesthesia

Hemodynamic Instability | Effect of Drug | Post-spinal Hypotension | Glycopyrrolate

Nepal
Milton S. Hershey Medical Center

Terminated

A New Optical Sweat Test Method Based on a Citric Acid-derived Multi-halide Sensor

Cystic Fibrosis

United States
Orion Corporation, Orion Pharma

Completed

Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler (FINDA)

Healthy Volunteers

Finland
Eurofarma Laboratorios S.A.

Not yet recruiting

Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) (TRIPLAR)

Chronic Obstructive Pulmonary Disease

Brazil
Pontificia Universidad Catolica de Chile

Completed

Pharmacokinetic and Pharmacodynamic of Rocuronium

Neuromuscular Blockade
Botanix Pharmaceuticals

Completed

Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301) (Cardigan I)

Axillary Hyperhidrosis

United States

3

Subscribe